

# Gene List

Guardant360 CDx is indicated to provide tumor mutation profiling for advanced cancer patients with any solid malignant neoplasm. Guardant360 CDx report contains both professional services, which includes 74 genes, in addition to the FDA-approved report, which includes 55 genes.

| Point Mutations (SNVs)<br>and Deletion Variants (Indels)<br>(74 Genes) |        |       |        |        | Amplifications<br>(18 Genes) |        | Fusions<br>(6 Genes) |
|------------------------------------------------------------------------|--------|-------|--------|--------|------------------------------|--------|----------------------|
|                                                                        |        |       |        |        | AR                           | FGFR1  | ALK                  |
| AKT1                                                                   | CDH1   | FGFR2 | KRAS   | NPM1   | BRAF                         | FGFR2  | FGFR2                |
| ALK                                                                    | CDK4   | FGFR3 | MAP2K1 | NRAS   | CCND1                        | KIT    | FGFR3                |
| APC                                                                    | CDK6   | GATA3 | MAP2K2 | NTRK1  | CCND2                        | KRAS   | NTRK1                |
| AR                                                                     | CDK12  | GNA11 | MAPK1  | NTRK3  | CCNE1                        | MET    | RET                  |
| ARAF                                                                   | CDKN2A | GNAQ  | MAPK3  | PDGFRA | CDK4                         | MYC    | ROS1                 |
| ARID1A                                                                 | CTNNB1 | GNAS  | MET    | PIK3CA | CDK6                         | PDGFRA |                      |
| ATM                                                                    | DDR2   | HNF1A | MLH1   | PTEN   | EGFR                         | PIK3CA |                      |
| BRAF                                                                   | EGFR   | HRAS  | MPL    | PTPN11 | ERBB2                        | RAF1   |                      |
| BRCA1                                                                  | ERBB2  | IDH1  | MTOR   | RAF1   |                              |        |                      |
| BRCA2                                                                  | ESR1   | IDH2  | MYC    | RB1    |                              |        |                      |
| CCND1                                                                  | EZH2   | JAK2  | NF1    | RET    |                              |        |                      |
| CCND2                                                                  | FBXW7  | JAK3  | NFE2L2 | RHEB   |                              |        |                      |
| CCNE1                                                                  | FGFR1  | KIT   | NOTCH1 | RHOA   |                              |        |                      |

Critical or all exons\* completely sequenced and all four major classes of alterations  
NSCLC guideline-recommended genes shown in bold / \*Exons selected to maximize detection of known somatic mutations / ^ Includes TERT promoter region

Guardant360 CDx Technical Information

Physician Insert

Advanced Beneficiary Notice



[Privacy Policy](#)   [Terms of Use](#)   [Notice of Privacy Practices](#)

© 2021 Guardant Health, Inc. All Rights Reserved

T: 1-855-698-8887  
F: 1-888-974-4258  
E: [clientservices@guardanthealth.com](mailto:clientservices@guardanthealth.com)

505 Penobscot Dr.  
Redwood City, CA 94063